Study identifier:D7830C00001
ClinicalTrials.gov identifier:NCT04142424
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight but Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
Metabolic disorders
Phase 1
Yes
AZD2693, Placebo
All
73
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Nov 2024 by AstraZeneca
AstraZeneca
PAREXEL
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in male and female subjects of non-childbearing potential in overweight but otherwise healthy subjects, and healthy Chinese and Japanese subjects.
This is a single center study, and approximately 64 overweight/mildly obese but otherwise healthy male and female subjects, and up to 16 healthy Japanese subjects and 8 healthy Chinese (all of non-childbearing potential) will be enrolled into this study. Study will consist of following planned cohorts: Eligible healthy subjects will be divided in 6 cohorts, each consisting of 8 subjects, within each cohort, 6 subjects will receive AZD2693 at dose level 1 and 2 subjects will receive placebo. Dosing for each ascending dose cohort will proceed with 2 subjects in a sentinel cohort, such that 1 subject will be randomized to receive placebo and 1 subject will be randomized to receive AZD2693. Eligible healthy Japanese and Chinese subjects will be divided as two cohorts of Japanese subjects, and one cohort of Chinese subjects. Each cohort will consist of 8 subjects. Within each cohort, 6 subjects will receive AZD2693 and 2 subjects will receive placebo. Depending on emerging data, up to 2 additional cohorts may be added to test additional dose levels based on Sponsor’s decision. Full study will comprise of following periods: 1. Screening period of maximum 28 days. 2. A Dosing Session during which subjects will be resident at the Clinical Unit from the day before investigational medicinal product (IMP) administration (Day -1) until at least 3 days after IMP administration with discharge on Day 4. 3. A Follow-Up Period of 16 weeks that will consist of 9 Follow-Up Visits, for which the subjects will return to the Clinical Unit at 1, 2, 4, 6, 8, 10, 12, 14, and 16 weeks post dose.
Location
Location
Glendale, CA, United States, 91206
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 healthy subjects: AZD2693 Dose 1 Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 2 healthy subjects: AZD2693 Dose 2 Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 3 healthy subjects: AZD2693 Dose 3 Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 4 healthy subjects: AZD2693 Dose 4 Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 5 healthy subjects: AZD2693 Dose 5 Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 6 healthy subjects: AZD2693 Dose 6 Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 7 healthy Japanese subjects: AZD2693 Dose 7 Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 8 healthy Japanese subjects: AZD2693 Dose 8 Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 9 healthy Chinese subjects: AZD2693 Dose 9 Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.